
CRISPR Therapeutics AG
CRSPHealthcare|Biotechnology|CH
$50.07
+1.51 (+3.11%)
Tangible Book / Share
$17.04
Cash / Share
$23.49
Next Earnings Report
Feb 11, 2027
EPS est. -$1.17 · Revenue est. $10.7M
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.
Upcoming Data Readouts (7)
Jun 2027
Est. completion
P1Cardiovascular
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
NCT07491172n=90
Jun 2027
Est. completion
P3Sickle Cell Disease
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
NCT05329649n=13
Nov 2027
Est. completion
P3Beta-Thalassemia
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
NCT05356195n=16
Jul 2028
Est. completion
P1P2Hypertension
A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension
NCT07758634n=69
Jan 2030
Est. completion
P1P2B-cell Lymphoma
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
NCT05643742n=120
Dec 2031
Est. completion
P1SLE (Systemic Lupus)
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
NCT06925542n=80
Dec 2033
Est. completion
P1P2Warm Autoimmune Hemolytic Anemia (WAIHA)
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
NCT07549698n=60
Recent Press Releases
CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases
Nov 8, 2026 · GlobeNewsWire
CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition
Nov 4, 2026 · GlobeNewsWire
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
Nov 2, 2026 · GlobeNewsWire
CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer
Nov 2, 2026 · GlobeNewsWire
CRISPR Therapeutics Announces Chief Financial Officer Transition
Oct 19, 2026 · GlobeNewsWire
CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026
Oct 8, 2026 · GlobeNewsWire
CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026
Oct 2, 2026 · GlobeNewsWire
CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Sep 8, 2026 · GlobeNewsWire
CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026
Aug 28, 2026 · GlobeNewsWire
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
Aug 10, 2026 · Globe News Wire
SEC Filings (52)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Nov 2, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Nov 2, 2026 | 8-K | Material event | DocumentIndex |
| Oct 19, 2026 | 8-K | Material event | DocumentIndex |
| Aug 14, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Aug 3, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Aug 3, 2026 | 8-K | Material event | DocumentIndex |
| Jul 27, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Jun 5, 2026 | S-8 | Employee stock plan | DocumentIndex |
| Jun 4, 2026 | 8-K | Material event | DocumentIndex |
| May 15, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| May 14, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| May 4, 2026 | 10-Q | Quarterly report | DocumentIndex |
| May 4, 2026 | 8-K | Material event | DocumentIndex |
| Apr 30, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Apr 21, 2026 | ARS | Annual report to holders | DocumentIndex |
| Apr 21, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Apr 21, 2026 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Apr 2, 2026 | PRE 14A | Proxy / shareholder vote | DocumentIndex |
| Mar 16, 2026 | 8-K | Material event | DocumentIndex |
| Mar 11, 2026 | 8-K | Material event | DocumentIndex |
| Feb 17, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Feb 12, 2026 | 10-K | Annual report | DocumentIndex |
| Feb 12, 2026 | 8-K | Material event | DocumentIndex |
| Feb 5, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Jan 12, 2026 | 8-K | Material event | DocumentIndex |
| Nov 14, 2025 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Nov 10, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Nov 10, 2025 | 8-K | Material event | DocumentIndex |
| Nov 4, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Oct 15, 2025 | 8-K | Material event | DocumentIndex |
| Oct 15, 2025 | 424B5 | Offering prospectus | DocumentIndex |
| Aug 4, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Aug 4, 2025 | 8-K | Material event | DocumentIndex |
| Jul 17, 2025 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Jun 26, 2025 | 8-K | Material event | DocumentIndex |
| Jun 9, 2025 | 8-K | Material event | DocumentIndex |
| May 19, 2025 | 424B5 | Offering prospectus | DocumentIndex |
| May 19, 2025 | 8-K | Material event | DocumentIndex |
| May 14, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| May 13, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |